Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling

Ching-Hsia Hung; Shih-Hung Chan; Pei-Ming Chu; Huei-Chen Lin; Kun-Ling Tsai

doi:10.18632/oncotarget.7387

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Gerotarget (Focus on Aging):

Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling

Ching-Hsia Hung _, Shih-Hung Chan, Pei-Ming Chu, Huei-Chen Lin and Kun-Ling Tsai

PDF | HTML | How to cite

Oncotarget. 2016; 7:10773-10787. https://doi.org/10.18632/oncotarget.7387

Metrics: PDF 2024 views | HTML 2706 views | ?

Abstract

Ching-Hsia Hung1,2, Shih-Hung Chan3, Pei-Ming Chu4, Huei-Chen Lin2,5 and Kun-Ling Tsai1

1 Department of Physical Therapy, College of Medicine, National Cheng Kung University,Tainan, Taiwan

2 Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

3 Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

4 Department of Anatomy, School of Medicine, China Medical University, Taichung, Taiwan

5 Department of Physical Therapy, Shu-Zen Junior College of Medicine and Management, Taiwan

Correspondence to:

Kun-Ling Tsai, email:

Keywords: metformin, endothelial dysfunction, oxLDL, SIRT1, Gerotarget

Received: January 02, 2016 Accepted: January 31, 2016 Published: February 14, 2016

Abstract

It is suggested that oxLDL is decisive in the initiation and development of atherosclerotic injuries. The up-regulation of oxidative stress and the generation of ROS act as key modulators in developing pro-atherosclerotic and anti-atherosclerotic processes in the human endothelial wall. In this present study, we confirmed that metformin enhanced SIRT1 and AMPK expression in human umbilical vein endothelial cells (HUVECs). Metformin also inhibited oxLDL-increased LOX-1 expression and oxLDL-collapsed AKT/eNOS levels. However, silencing SIRT1 and AMPK diminished the protective function of metformin against oxidative injuries. These results provide a new insight regarding the possible molecular mechanisms of metformin.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7387

Publication Alerts

Research Papers: Gerotarget (Focus on Aging):

Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling

Abstract